Jacqueline Bezençon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jacqueline Bezençon has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Kim L. R. Brouwer
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
9 shared publications - James John Beaudoin
Quantitative Systems Pharmacology Solutions, Simulations Plus, Inc. Chapel Hill North Carolina USA
6 shared publications - John Kevin Fallon
Division of Pharmacoengineering and Molecular Pharmaceutics, and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
6 shared publications - Beat Ernst
Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
4 shared publications - Martin Smieško
Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
4 shared publications Oliver Schwardt
4 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Novel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- Open Access
- 15 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Advancing Pregnancy and Pediatric Science through the NIH Transporter Elucidation Network
Human gestation is characterized by dynamic changes in maternal physiology and maturation of tissue functions before and after birth. The fetus and neonate are highly dependent upon transfer of maternal nutrients via the placenta and lactating mammary gland, which frequently involve selective membrane transporter proteins. At the same time, developmental changes in fetal and infant transport mechanisms critical for regulating absorption at the intestinal and blood–brain barriers are occurring. Coordinate regulation of cellular entry and efflux of nutrients, supplements, and xenobiotics, including drugs and environmental chemicals, must occur during this critical developmental period. In 2023, the National Institutes of Health launched the Transporter Elucidation Network (TEN) across four centers. This initiative applies experimental, computational, and translational approaches to (1) identify S o L ute C arrier (SLC) superfamily and A TP‐ b inding c assette (ABC) transporters in the human placenta, mammary gland, as well as the pediatric brain and intestinal barriers and, (2) characterize their localization, expression, function, and regulation. The Network seeks to identify functional determinants of transporters as gatekeepers of entry to placenta, mammary gland and brain, and applies structural biology, proteomics, metabolomics, organoids, liquid biopsies, and microphysiological systems to this end. Computational strategies, such as machine learning, virtual screening, physiologically based pharmacokinetics, and perinatal epidemiology complement our experimental approaches. This paper highlights the TEN's multidisciplinary strategies to address current challenges in perinatal and pediatric transporter research and its commitment to advancing state‐of‐the‐art tools and new approach methodologies to fill critical gaps in our understanding of nutrient and xenobiotic exposure during early human development.
- 15 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessAdvancing Pregnancy and Pediatric Science through the NIH Transporter Elucidation Network
Human gestation is characterized by dynamic changes in maternal physiology and maturation of tissue functions before and after birth. The fetus and neonate are highly dependent upon transfer of maternal nutrients via the placenta and lactating mammary gland, which frequently involve selective membrane transporter proteins. At the same time, developmental changes in fetal and infant transport mechanisms critical for regulating absorption at the intestinal and blood–brain barriers are occurring. Coordinate regulation of cellular entry and efflux of nutrients, supplements, and xenobiotics, including drugs and environmental chemicals, must occur during this critical developmental period. In 2023, the National Institutes of Health launched the Transporter Elucidation Network (TEN) across four centers. This initiative applies experimental, computational, and translational approaches to (1) identify S o L ute C arrier (SLC) superfamily and A TP‐ b inding c assette (ABC) transporters in the human placenta, mammary gland, as well as the pediatric brain and intestinal barriers and, (2) characterize their localization, expression, function, and regulation. The Network seeks to identify functional determinants of transporters as gatekeepers of entry to placenta, mammary gland and brain, and applies structural biology, proteomics, metabolomics, organoids, liquid biopsies, and microphysiological systems to this end. Computational strategies, such as machine learning, virtual screening, physiologically based pharmacokinetics, and perinatal epidemiology complement our experimental approaches. This paper highlights the TEN's multidisciplinary strategies to address current challenges in perinatal and pediatric transporter research and its commitment to advancing state‐of‐the‐art tools and new approach methodologies to fill critical gaps in our understanding of nutrient and xenobiotic exposure during early human development.
- Open Access
- 13 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1368-1378
Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes (DMEs), particularly at the protein level. In this study, we characterized a liver tissue chip (LTC) as a new approach methodology (NAM) for long‐term transporter‐ and DME‐mediated induction risk assessment. Transporter‐certified® cryopreserved primary human hepatocytes from three donors were cultured in the LTC under recirculating flow with or without 10 μM rifampicin for 7 days. The LTC facilitated simultaneous mRNA‐protein quantification for transporters and mRNA‐protein‐activity profiling for cytochrome P450s (CYPs) within individual chips across treatment and control conditions. In addition, extracellular bile acid profiling and intracellular rifampicin concentrations were measured by LC–MS/MS. Rifampicin induced multiple transporters and enzymes at the protein level, including organic anion transporting polypeptide (OATP)2B1, P‐glycoprotein, CYP3A4, CYP2C19, and uridine 5’‐diphospho‐glucuronosyltransferase (UGT)1A4. Induction patterns differed between transporter mRNA and protein in many cases, suggesting regulatory mechanisms beyond PXR‐mediated activation. Matched mRNA‐protein‐activity measurements of five CYP enzymes also revealed discrepancies in rifampicin‐mediated induction magnitude. Rifampicin altered bile acid composition, increasing taurine‐conjugated bile acids and inducing bile acid‐related genes. Measured intracellular rifampicin concentrations differed substantially from experimentally employed media concentrations. Overall, these findings demonstrate that the LTC enables integrated assessment of mRNA, protein, and activity measurements in addition to bile acid profiles and intracellular drug exposure, which may improve mechanistic understanding of induction processes.
- 13 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1368-1378
Open AccessIntegrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes (DMEs), particularly at the protein level. In this study, we characterized a liver tissue chip (LTC) as a new approach methodology (NAM) for long‐term transporter‐ and DME‐mediated induction risk assessment. Transporter‐certified® cryopreserved primary human hepatocytes from three donors were cultured in the LTC under recirculating flow with or without 10 μM rifampicin for 7 days. The LTC facilitated simultaneous mRNA‐protein quantification for transporters and mRNA‐protein‐activity profiling for cytochrome P450s (CYPs) within individual chips across treatment and control conditions. In addition, extracellular bile acid profiling and intracellular rifampicin concentrations were measured by LC–MS/MS. Rifampicin induced multiple transporters and enzymes at the protein level, including organic anion transporting polypeptide (OATP)2B1, P‐glycoprotein, CYP3A4, CYP2C19, and uridine 5’‐diphospho‐glucuronosyltransferase (UGT)1A4. Induction patterns differed between transporter mRNA and protein in many cases, suggesting regulatory mechanisms beyond PXR‐mediated activation. Matched mRNA‐protein‐activity measurements of five CYP enzymes also revealed discrepancies in rifampicin‐mediated induction magnitude. Rifampicin altered bile acid composition, increasing taurine‐conjugated bile acids and inducing bile acid‐related genes. Measured intracellular rifampicin concentrations differed substantially from experimentally employed media concentrations. Overall, these findings demonstrate that the LTC enables integrated assessment of mRNA, protein, and activity measurements in addition to bile acid profiles and intracellular drug exposure, which may improve mechanistic understanding of induction processes.
- Open Access
- 27 June 2026
- Published by Elsevier in SSRN Electronic Journal
Novel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies result in incomplete heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis, and siRNA-mediated ALAS1 silencing (e.g., Givlaari®) has validated ALAS1 as a clinical target for acute hepatic porphyria (AHP). Recently we identified a class of small molecules that promote ALAS1 degradation. One of these compounds is ONC201 (dordaviprone, Modeyso®), an orally available small molecule recently approved by the FDA for the treatment of glioma. ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). Upon ClpP activation, ALAS1 is robustly degraded in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting in multiple cell models. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies demonstrate that ClpP agonists are highly effective and rapidly-acting small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these pre-clinical studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- 27 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies result in incomplete heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis, and siRNA-mediated ALAS1 silencing (e.g., Givlaari®) has validated ALAS1 as a clinical target for acute hepatic porphyria (AHP). Recently we identified a class of small molecules that promote ALAS1 degradation. One of these compounds is ONC201 (dordaviprone, Modeyso®), an orally available small molecule recently approved by the FDA for the treatment of glioma. ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). Upon ClpP activation, ALAS1 is robustly degraded in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting in multiple cell models. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies demonstrate that ClpP agonists are highly effective and rapidly-acting small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these pre-clinical studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- Open Access
- 30 December 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Evaluation of a human 3D multicellular hepatic spheroid model as a platform for studying hepatic transporters
There is growing demand for improved in vitro liver models to better predict in vivo pharmacology, specifically drug disposition mediated by hepatic transporters and assessment of transporter-mediated drug interaction risk. While 2D sandwich-cultured human hepatocytes (SCHH) remain valuable, they are limited to short-term use due to hepatocyte de-differentiation and absence of non-parenchymal cells. Multicellular hepatic spheroids (MHS) offer a promising alternative, but transporter concentrations, functionality, and suitability for hepatobiliary transport studies remain unclear. We evaluated an all-human MHS model, comprised of transporter-certified™ cryopreserved primary human hepatocytes (PHH), Kupffer, stellate, and endothelial cells, for long-term hepatic transporter assessment. Over a 21-day culture period, we monitored transporter concentrations (targeted proteomics), regulation (RNA-seq), localization (immunofluorescence), bile acid profiles (LC–MS/MS), and functional transport (B-CLEAR®). This is the first report of protein concentrations of 13 transporters in MHS over 21 days directly compared to freshly thawed PHH and SCHH from the same donor. Most transporters declined in MHS compared to PHH, while SCHH maintained or increased transporter concentrations by day 5. However, multidrug resistance-associated protein (MRP) 4 and organic solute transporter (OST)-α/β were upregulated in MHS, likely reflecting adaptation to bile acid accumulation. Bile acid profiling confirmed functional synthesis, metabolism and excretion. Functional MRP2 efflux into sealed canalicular compartments was demonstrated with the MRP2 substrate, 5(6)-carboxy-2′,7′-dichlorofluorescein (CDF). Tight junction disruption of canaliculi with Ca2⁺-free buffer resulted in CDF release from canalicular compartments, with partial entrapment within MHS, likely due to the 3D architecture. These findings highlight key strengths and limitations of MHS as a model for assessing hepatobiliary transport.
- 30 December 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessEvaluation of a human 3D multicellular hepatic spheroid model as a platform for studying hepatic transporters
There is growing demand for improved in vitro liver models to better predict in vivo pharmacology, specifically drug disposition mediated by hepatic transporters and assessment of transporter-mediated drug interaction risk. While 2D sandwich-cultured human hepatocytes (SCHH) remain valuable, they are limited to short-term use due to hepatocyte de-differentiation and absence of non-parenchymal cells. Multicellular hepatic spheroids (MHS) offer a promising alternative, but transporter concentrations, functionality, and suitability for hepatobiliary transport studies remain unclear. We evaluated an all-human MHS model, comprised of transporter-certified™ cryopreserved primary human hepatocytes (PHH), Kupffer, stellate, and endothelial cells, for long-term hepatic transporter assessment. Over a 21-day culture period, we monitored transporter concentrations (targeted proteomics), regulation (RNA-seq), localization (immunofluorescence), bile acid profiles (LC–MS/MS), and functional transport (B-CLEAR®). This is the first report of protein concentrations of 13 transporters in MHS over 21 days directly compared to freshly thawed PHH and SCHH from the same donor. Most transporters declined in MHS compared to PHH, while SCHH maintained or increased transporter concentrations by day 5. However, multidrug resistance-associated protein (MRP) 4 and organic solute transporter (OST)-α/β were upregulated in MHS, likely reflecting adaptation to bile acid accumulation. Bile acid profiling confirmed functional synthesis, metabolism and excretion. Functional MRP2 efflux into sealed canalicular compartments was demonstrated with the MRP2 substrate, 5(6)-carboxy-2′,7′-dichlorofluorescein (CDF). Tight junction disruption of canaliculi with Ca2⁺-free buffer resulted in CDF release from canalicular compartments, with partial entrapment within MHS, likely due to the 3D architecture. These findings highlight key strengths and limitations of MHS as a model for assessing hepatobiliary transport.
- Open Access
- 25 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (1)
Comparison of Metformin PBPK Models Incorporating Placental Transfer to Predict Fetal and Maternal Exposure
Physiologically based pharmacokinetic (PBPK) modeling of placental drug transfer is an evolving tool for predicting fetal drug exposure. In this study, a pregnancy‐specific metformin PBPK model was developed, and the following four approaches were evaluated to predict metformin placental transfer: (1) perfusion‐limited model, and permeability‐limited models using (2) ex vivo cotyledon open system apparent clearance, (3) ex vivo cotyledon closed system data fit to a three‐compartment model to estimate clearance, and (4) active transport kinetics and passive clearance. Simulated metformin maternal plasma concentrations (MPCs) and umbilical cord venous plasma concentrations (UCCs) were compared to observed in vivo data from subjects with gestational diabetes mellitus taking metformin 500 mg twice daily. Model selection criteria were determined by the percentage of observed clinical data falling within the 5th to 95th percentiles of the simulated population. Among the approaches, the model that included passive permeability and in vitro intrinsic transporter clearances (Approach 4) best described placental metformin transfer, with 92% of UCCs falling within the 5th to 95th percentiles of the simulated population. Furthermore, maternal uptake transport had the largest influence on predicted UCCs. A two‐fold increase in maternal uptake transport increased the predicted population mean UCC C max by 97%, whereas a 0.5‐fold decrease resulted in a 49% decrease in UCC C max . This refined PBPK model offers a valuable framework for predicting placental transfer and fetal exposure of metformin when placental transporters are altered throughout pregnancy and/or with pathological conditions.
- 25 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (1)
Open AccessComparison of Metformin PBPK Models Incorporating Placental Transfer to Predict Fetal and Maternal Exposure
Physiologically based pharmacokinetic (PBPK) modeling of placental drug transfer is an evolving tool for predicting fetal drug exposure. In this study, a pregnancy‐specific metformin PBPK model was developed, and the following four approaches were evaluated to predict metformin placental transfer: (1) perfusion‐limited model, and permeability‐limited models using (2) ex vivo cotyledon open system apparent clearance, (3) ex vivo cotyledon closed system data fit to a three‐compartment model to estimate clearance, and (4) active transport kinetics and passive clearance. Simulated metformin maternal plasma concentrations (MPCs) and umbilical cord venous plasma concentrations (UCCs) were compared to observed in vivo data from subjects with gestational diabetes mellitus taking metformin 500 mg twice daily. Model selection criteria were determined by the percentage of observed clinical data falling within the 5th to 95th percentiles of the simulated population. Among the approaches, the model that included passive permeability and in vitro intrinsic transporter clearances (Approach 4) best described placental metformin transfer, with 92% of UCCs falling within the 5th to 95th percentiles of the simulated population. Furthermore, maternal uptake transport had the largest influence on predicted UCCs. A two‐fold increase in maternal uptake transport increased the predicted population mean UCC C max by 97%, whereas a 0.5‐fold decrease resulted in a 49% decrease in UCC C max . This refined PBPK model offers a valuable framework for predicting placental transfer and fetal exposure of metformin when placental transporters are altered throughout pregnancy and/or with pathological conditions.
- 16 October 2025
- Published by Elsevier in Pharmacological Reviews
- Vol. 78 (1) , 100100
Modeling lung transporters and their influence on inhaled drug disposition
- 16 October 2025
- Published by Elsevier in Pharmacological Reviews
- Vol. 78 (1) , 100100
Modeling lung transporters and their influence on inhaled drug disposition
- 4 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (2) , 394-407
Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
Therapeutic antibodies are often prescribed off‐label to pregnant patients to treat inflammatory, autoimmune, or malignant conditions. Despite their broad use, the extent of fetal exposure to such therapeutic antibodies and the risk to fetal development remain largely unknown. Given the ethical challenges to conduct randomized trials in pregnant patients, modeling and simulation approaches offer an opportunity to yield mechanistic insights using data from observational studies. In this study, a physiologically based pharmacokinetic (PBPK) modeling framework was developed to predict maternal and fetal therapeutic antibody exposures throughout pregnancy. The model incorporates expression data on the placental neonatal Fc receptor (FcRn), a receptor critical to transplacental IgG transfer. FcRn‐mediated transplacental antibody transfer was described by three endosomal compartments: (1) maternal vascular endothelial cells; (2) syncytiotrophoblast cells; and (3) fetal vascular endothelial cells. The model was calibrated and validated using endogenous IgG concentrations and pharmacokinetic data from > 2,000 non‐pregnant subjects, 167 pregnant women, and 268 infants. Overall, the minimal PBPK model adequately captured the observations, with predictions falling within a twofold range of maternal and fetal concentrations as follows: infliximab (54% and 50%), adalimumab (100% and 70%), ustekinumab (38% and 41%), vedolizumab (92% and 77%), and etanercept (75% and 33%). In addition, the PBPK framework supported the evaluation of infliximab and adalimumab dosing regimens that maintain maternal therapeutic levels while minimizing fetal exposure. This study provides a generalizable PBPK framework including FcRn ontogeny, implemented in a user‐friendly tool, to predict transplacental transfer of many biologics and to support appropriate dosing regimens throughout pregnancy.
- 4 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (2) , 394-407
Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
Therapeutic antibodies are often prescribed off‐label to pregnant patients to treat inflammatory, autoimmune, or malignant conditions. Despite their broad use, the extent of fetal exposure to such therapeutic antibodies and the risk to fetal development remain largely unknown. Given the ethical challenges to conduct randomized trials in pregnant patients, modeling and simulation approaches offer an opportunity to yield mechanistic insights using data from observational studies. In this study, a physiologically based pharmacokinetic (PBPK) modeling framework was developed to predict maternal and fetal therapeutic antibody exposures throughout pregnancy. The model incorporates expression data on the placental neonatal Fc receptor (FcRn), a receptor critical to transplacental IgG transfer. FcRn‐mediated transplacental antibody transfer was described by three endosomal compartments: (1) maternal vascular endothelial cells; (2) syncytiotrophoblast cells; and (3) fetal vascular endothelial cells. The model was calibrated and validated using endogenous IgG concentrations and pharmacokinetic data from > 2,000 non‐pregnant subjects, 167 pregnant women, and 268 infants. Overall, the minimal PBPK model adequately captured the observations, with predictions falling within a twofold range of maternal and fetal concentrations as follows: infliximab (54% and 50%), adalimumab (100% and 70%), ustekinumab (38% and 41%), vedolizumab (92% and 77%), and etanercept (75% and 33%). In addition, the PBPK framework supported the evaluation of infliximab and adalimumab dosing regimens that maintain maternal therapeutic levels while minimizing fetal exposure. This study provides a generalizable PBPK framework including FcRn ontogeny, implemented in a user‐friendly tool, to predict transplacental transfer of many biologics and to support appropriate dosing regimens throughout pregnancy.
- 26 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 21 (4) , 445-462
Mechanisms of altered hepatic drug disposition during pregnancy: small molecules
Pregnancy alters the systemic exposure and clearance of many hepatically cleared drugs that are commonly used by obstetric patients. Understanding the molecular mechanisms underlying the changes in factors that affect hepatic drug clearance (blood flow, protein binding, and intrinsic clearance) is essential to more precisely predict systemic drug exposure and dose requirements in obstetric patients. This review (1) summarizes the anatomic, physiologic, and biochemical changes in maternal hepatic, cardiovascular, endocrine, and renal systems relevant to hepatic drug clearance and (2) reviews the molecular mechanisms underlying the altered hepatic metabolism and intrinsic clearance of drugs during pregnancy via a comprehensive PubMed search. It also identifies knowledge gaps in the molecular mechanisms and factors that modulate hepatic drug clearance during pregnancy. Pharmacokinetic studies have shown that pregnancy alters systemic exposure, protein binding, and clearance of many drugs during gestation in part due to pregnancy-associated decreases in plasma albumin, increases in organ blood flow, and changes in the activity of drug-metabolizing enzymes (DMEs) and transporters. The changes in the activity of certain DMEs and transporters during pregnancy are likely driven by hormonal-changes that inhibit their activity or alter the expression of these proteins through activation of transcription factors.
- 26 February 2025
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 21 (4) , 445-462
Mechanisms of altered hepatic drug disposition during pregnancy: small molecules
Pregnancy alters the systemic exposure and clearance of many hepatically cleared drugs that are commonly used by obstetric patients. Understanding the molecular mechanisms underlying the changes in factors that affect hepatic drug clearance (blood flow, protein binding, and intrinsic clearance) is essential to more precisely predict systemic drug exposure and dose requirements in obstetric patients. This review (1) summarizes the anatomic, physiologic, and biochemical changes in maternal hepatic, cardiovascular, endocrine, and renal systems relevant to hepatic drug clearance and (2) reviews the molecular mechanisms underlying the altered hepatic metabolism and intrinsic clearance of drugs during pregnancy via a comprehensive PubMed search. It also identifies knowledge gaps in the molecular mechanisms and factors that modulate hepatic drug clearance during pregnancy. Pharmacokinetic studies have shown that pregnancy alters systemic exposure, protein binding, and clearance of many drugs during gestation in part due to pregnancy-associated decreases in plasma albumin, increases in organ blood flow, and changes in the activity of drug-metabolizing enzymes (DMEs) and transporters. The changes in the activity of certain DMEs and transporters during pregnancy are likely driven by hormonal-changes that inhibit their activity or alter the expression of these proteins through activation of transcription factors.
- 24 September 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 353-364
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non‐clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug‐induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin‐I (CP‐I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B‐mediated DDI risk in humans. In this clinical observational cohort‐comparison study, bile acid profiles and CP‐I concentrations in healthy volunteers and patients with ADPKD were compared.Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP‐I concentrations, were quantified by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS).Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3‐fold) and taurine‐conjugated (2.8‐fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5‐, 2.9‐, 2.8‐, 1.6‐, 1.7‐ and 2.7‐fold, respectively) in patients with ADPKD. Furthermore, serum CP‐I concentrations were elevated and the renal clearance of CP‐I was reduced in patients with ADPKD compared to healthy volunteers.Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP‐I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.
- 24 September 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (2) , 353-364
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non‐clinical model of polycystic kidney disease. Similar changes in patients with autosomal dominant polycystic kidney disease (ADPKD) may predispose them to drug‐induced liver injury (DILI) and hepatic drug–drug interactions (DDIs). Systemic coproporphyrin‐I (CP‐I), an endogenous biomarker for hepatic OATP1B function and MRP2 substrate, is used to evaluate OATP1B‐mediated DDI risk in humans. In this clinical observational cohort‐comparison study, bile acid profiles and CP‐I concentrations in healthy volunteers and patients with ADPKD were compared.Methods: Serum and urine samples from healthy volunteers (n = 16) and patients with ADPKD (n = 8) were collected. Serum bile acids, and serum and urine CP‐I concentrations, were quantified by ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS).Results: Patients with ADPKD exhibited increased serum concentrations of total (1.3‐fold) and taurine‐conjugated (2.8‐fold) bile acids compared to healthy volunteers. Specifically, serum concentrations of six bile acids known to be more hydrophobic/hepatotoxic (glycochenodeoxycholate, taurochenodeoxycholate, taurodeoxycholate, lithocholate, glycolithocholate and taurolithocholate) were increased (1.5‐, 2.9‐, 2.8‐, 1.6‐, 1.7‐ and 2.7‐fold, respectively) in patients with ADPKD. Furthermore, serum CP‐I concentrations were elevated and the renal clearance of CP‐I was reduced in patients with ADPKD compared to healthy volunteers.Conclusions: Increased exposure to bile acids may increase susceptibility to DILI in some patients with ADPKD. Furthermore, the observed increase in serum CP‐I concentrations could be attributed, in part, to impaired OATP1B function in patients with ADPKD, which could increase the risk of DDIs involving OATP1B substrates compared to healthy volunteers.